secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001628280-25-012899
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis reports azenosertib ORR ~35% and mDOR 6.3 months in Cyclin E1+ PROC; Part 2 initiation on track for 1H2025
--------------------------------------------------------------------------------

- Azenosertib demonstrated ORR of 34.9% (15/43) in response-evaluable Cyclin E1+ PROC patients; mDOR 6.3 months (95% CI: 2.7–NE) as of Jan 13, 2025 cutoff.
- Cyclin E1 overexpression by IHC identified as predictive biomarker; ~50% of PROC patients overexpress Cyclin E1.
- Safety profile consistent; most common TRAEs were GI toxicities and fatigue; 21.6% discontinued due to TRAEs.
- Initiation of DENALI Part 2 in 1H 2025 on track; registration-intent topline data expected by year end 2026.
- Preclinical data show synergistic antitumor effects of azenosertib combined with microtubule inhibitor-based ADCs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000162828025012899/0001628280-25-012899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000162828025012899/zntl-20250315.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-012899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer